Oxycodone for cancer-related pain.

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Cochrane Database of Systematic Reviews

• Publication date

  2017-08-22

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/14651858.CD003870.pub6PMID 28829910PMCID PMC6421939
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Efficacy, tolerability and acceptability of oxycodone for cancer-related pain in adults: an updated Cochrane systematic review

  2018cited by this paper
• Opioid prescribing for patients with cancer in the last year of life: a longitudinal population cohort study

  2016cited by this paper
• Comparison of the Tolerability Profile of Controlled-Release Oral Morphine and Oxycodone for Cancer Pain Treatment. An Open-Label Randomized Controlled Trial.

  2016cited by this paper
• The Adverse Events of Oxycodone in Cancer-Related Pain

  2016cited by this paper
• Are strong opioids equally effective and safe in the treatment of chronic cancer pain? A multicenter randomized phase IV 'real life' trial on the variability of response to opioids.

  2016cited by this paper
• Opioid prescribing for cancer patients in the last year of life: a longitudinal population cohort study

  2015cited by this paper
• Morphine or oxycodone for cancer-related pain? A randomized, open-label, controlled trial.

  2015cited by this paper
• Oxycodone for Cancer Pain in Adult Patients.

  2015cited by this paper
• A Systematic Review of Prospective Studies Reporting Adverse Events of Commonly Used Opioids for Cancer-Related Pain: A Call for the Use of Standardized Outcome Measures.

  2015cited by this paper
• Opioid rotation versus combination for cancer patients with chronic uncontrolled pain: a randomized study

  2015cited by this paper
• Oxycodone Frequently Induced Nausea and Vomiting in Oxycodone-Naïve Patients with Hepatic Dysfunction

  2015cited by this paper
• Observation of Curative Effects and Adverse Effects of Oxycodone Hydrochloride Controlled-release Tablets and Fentanyl Transdermal Patches on the treatment of Moderate or Severe Cancer Pain

  2015cited by this paper
• Clinical evaluation of the first oxycodone once daily prolonged release tablet in moderate to severe chronic pain: a randomized, double-blind, multicenter, cross-over, non-inferiority study to investigate efficacy and safety in comparison with an established oxycodone twice daily prolonged release t

  2014cited by this paper
• Pharmacoeconomics evaluation of morphine, MS contin and oxycodone in the treatment of cancer pain.

  2014cited by this paper
• Aberrant drug-related behavior observed during a 12-week open-label extension period of a study involving patients taking chronic opioid therapy for persistent pain and fentanyl buccal tablet or traditional short-acting opioid for breakthrough pain.

  2014cited by this paper
• Quality of cancer pain management: an update of a systematic review of undertreatment of patients with cancer.

  2014cited by this paper
• Safety and efficacy of once-daily hydromorphone extended-release versus twice-daily oxycodone hydrochloride controlled-release in chinese patients with cancer pain: a phase 3, randomized, double-blind, multicenter study.

  2014cited by this paper
• Lack of correlation between the effective dose of fentanyl sublingual spray for breakthrough cancer pain and the around-the-clock opioid dose.

  2014cited by this paper
• Quality of Life Benefits and Cost Impact of Prolonged Release Oxycodone/Naloxone Versus Prolonged Release Oxycodone in Patients with Moderate to Severe Pain and Opioid-Induced Constipation Despite the Use of 2 Laxatives: A UK Cost Utility Analysis

  2013cited by this paper
• Lack of correlation between the dose of fentanyl sublingual spray for breakthrough cancer pain and the dose of around-the-clock opioid for persistent pain

  2013cited by this paper
• Efficacy and safety of oral tapentadol extended release in Japanese and Korean patients with moderate to severe, chronic malignant tumor-related pain

  2013cited by this paper
• Intravesical Baclofen, Bupivacaine, and Oxycodone for the relief of Bladder Spasm

  2013cited by this paper
• Randomised Phase II Trial (NCT00637975) Evaluating Activity and Toxicity of Two Different Escalating Strategies for Pregabalin and Oxycodone Combination Therapy for Neuropathic Pain in Cancer Patients

  2013cited by this paper
• Quality of life benefits and cost impact of prolonged release oxycodone/naloxone versus prolonged release oxycodone in patients with moderate-to-severe non-malignant pain and opioid-induced constipation: a UK cost-utility analysis

  2012cited by this paper
• Scrambler therapy may relieve chronic neuropathic pain more effectively than guideline-based drug management: results of a pilot, randomized, controlled trial.

  2012cited by this paper
• Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC.

  2012cited by this paper
• A systematic review of randomized trials on the effectiveness of opioids for cancer pain.

  2012cited by this paper
• A randomized, double-blind, active-controlled, double-dummy, parallel-group study to determine the safety and efficacy of oxycodone/naloxone prolonged-release tablets in patients with moderate/severe, chronic cancer pain

  2012cited by this paper
• Serum concentrations of opioids when comparing two switching strategies to methadone for cancer pain

  2012cited by this paper
• Efficacy and tolerability of oxycodone in moderate-severe cancer-related pain: A meta-analysis of randomized controlled trials.

  2012cited by this paper
• Opioid therapies and cytochrome p450 interactions.

  2012cited by this paper
• Efficacy of oxycodone/paracetamol for patients with bone‐cancer pain: a multicenter, randomized, double‐blinded, placebo‐controlled trial

  2012cited by this paper
• Is oral morphine still the first choice opioid for moderate to severe cancer pain? A systematic review within the European Palliative Care Research Collaborative guidelines project

  2011cited by this paper
• A systematic review of combination step III opioid therapy in cancer pain: An EPCRC opioid guideline project

  2011cited by this paper
• A systematic review of oxycodone in the management of cancer pain

  2011cited by this paper
• Can morphine still be considered to be the standard for treating chronic pain? A systematic review including pair-wise and network meta-analyses

  2011cited by this paper
• Facial affect processing in patients receiving opioid treatment in palliative care: preferential processing of threat in pain catastrophizers.

  2011cited by this paper
• F612 LONG-TERM EFFICACY AND SAFETY OF THE FIXED COMBINATION OXYCODONE AND NALOXONE PROLONGED RELEASE (PR) IN PATIENTS WITH CHRONIC CANCER PAIN

  2011cited by this paper
• Should opioids be used for chronic non‐cancer pain?

  2011cited by this paper
• Final results of a randomized phase II trial (NCT00637975) evaluating activity and toxicity of fixed-dose oxycodone and increasing dose of pregabalin versus increasing dose of oxycodone and fixed-dose pregabalin for the treatment of oncologic neuropathic pain (NEUROPAIN-01).

  2011cited by this paper
• Controlled-release oxycodone alone or combined with gabapentin for management of malignant neuropathic pain

  2010cited by this paper
• A randomized comparison of oral methadone as a “first-switch” opioid versus opioid switching between sustained-release morphine and oxycodone for oncology outpatients with pain management problems.

  2010cited by this paper
• Morphine Versus Oxycodone in Pancreatic Cancer Pain: A Randomized Controlled Study

  2010cited by this paper
• Role of oxycodone and oxycodone/naloxone in cancer pain management

  2010cited by this paper
• Effect of the inhibition of CYP3A4 or CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone

  2010cited by this paper
• Oxycodone for cancer‐related pain

  2010cited by this paper
• Oxycodone/acetaminophen addition to constant opioids in metastatic bone pain: A randomized, double-blinded, controlled, multicenter trial.

  2010cited by this paper
• Efficacies of oxycodone and morphine sulfate sustained-release tablets in treating moderate and severe cancer pain

  2009cited by this paper
• Cancer-related pain: a pan-European survey of prevalence, treatment, and patient attitudes.

  2009cited by this paper
• Effectiveness of topical administration of opioids in palliative care: a systematic review.

  2009cited by this paper
• Validation of the Bowel Function Index to detect clinically meaningful changes in opioid-induced constipation

  2009cited by this paper
• Efficacy and safety of oxycodone-acetaminophen for moderate and severe visceral pain in advanced cancer patients

  2009cited by this paper
• Efficacy of oxycodone-acetominophen by different administrations in controlling moderate to severe cancer pain and break-out pain

  2009cited by this paper
• Efficacy of oxycodone-acetaminophen as an adjuvant of opioid analgesics for cancer pain

  2009cited by this paper
• Evaluation of efficacy and safety of prolonged-release oxycodone at different dosages for the treatment of severe chronic pain

  2009cited by this paper
• A Randomized Double-Blind Crossover Comparison of Continuous and Intermittent Subcutaneous Administration of Opioid for Cancer Pain

  2008cited by this paper
• Prevalence of undertreatment in cancer pain. A review of published literature.

  2008cited by this paper
• Patient assessment of a novel therapeutic approach for the treatment of severe, chronic pain

  2008cited by this paper
• Oxycodone and the Challenge of Neuropathic Cancer Pain: A Review

  2008cited by this paper
• Decreasing use of controlled-release oxycodone: response to Morden et al, June 2008 Medical Care.

  2008cited by this paper
• Analgesic effect of oxycodone-acetaminophen tablets in patients with cervical cancer

  2008cited by this paper
• Efficacy and safety of oxycodone-acetaminophen tablet in 142 patients with different types of moderate and advanced cancer pain

  2008cited by this paper
• Oxycodone for cancer-related pain: meta-analysis of randomized controlled trials.

  2006cited by this paper
• Controlled clinical trials in cancer pain. How controlled should they be? A qualitative systematic review

  2006cited by this paper
• Establishing the dosage equivalency of oxymorphone extended release and oxycodone controlled release in patients with cancer pain: a randomized controlled study

  2004cited by this paper
• [Use of opioids against severe cancer pain].

  2004cited by this paper
• Comparison of sustained-release morphine with sustained-release oxycodone in advanced cancer patients

  2003cited by this paper
• [Extended release oxycodone. An oral opioid analgesic for cancer patients with chronic pain].

  2002cited by this paper
• Double‐Blind, Randomized Comparison of the Analgesic and Pharmacokinetic Profiles of Controlled‐ and Immediate‐Release Oral Oxycodone in Cancer Pain Patients

  2001cited by this paper
• Morphine or oxycodone in cancer pain?

  2000cited by this paper
• Can a controlled-release oral dose form of oxycodone be used as readily as an immediate-release form for the purpose of titrating to stable pain control?

  1999cited by this paper
• Wherefore global quality-of-life assessment? [6] (multiple letters)

  1999cited by this paper
• Efficacy of controlled-release oxycodone.

  1999cited by this paper
• Controlled‐release oxycodone compared with controlled‐release morphine in the treatment of cancer pain: A randomized, double‐blind, parallel‐group study

  1998cited by this paper
• Comparison of controlled-release and immediate-release oxycodone tablets in patients with cancer pain.

  1998cited by this paper
• The use of controlled-release oxycodone for the treatment of chronic cancer pain: a randomized, double-blind study.

  1998cited by this paper
• Randomized, double-blind, cross-over trial comparing safety and efficacy of oral controlled-release oxycodone with controlled-release morphine in patients with cancer pain.

  1998cited by this paper
• Comparative clinical efficacy and safety of a novel controlled‐release oxycodone formulation and controlled‐release hydromorphone in the treatment of cancer pain

  1997cited by this paper
• Controlled‐release oxycodone and morphine in cancer related pain

  1997cited by this paper
• Pharmacokinetics and Pharmacodynamics of Oxycodone When Given Intravenously and Rectally to Adult Patients with Cancer Pain

  1995cited by this paper
• The dose-response relationship of controlled-release codeine (Codeine Contin) in chronic cancer pain.

  1994cited by this paper
• A clinical study on the use of codeine, oxycodone, dextropropoxyphene, buprenorphine, and pentazocine in cancer pain.

  1991cited by this paper
• Morphine and oxycodone hydrochloride in the management of cancer pain

  1990cited by this paper
• Morphine and oxycodone in the management of cancer pain: plasma levels determined by chemical and radioreceptor assays.

  1990cited by this paper
• A validation study of the WHO method for cancer pain relief

  1987cited by this paper
• Analgesic Efficacy of Zomepirac Sodium in Patients with Pain Due to Cancer

  1981cited by this paper
• Double‐Blind Comparisons of Zomepirac and Oxycodone with APC in Cancer Pain

  1980cited by this paper
• Analgesic studies of codeine and oxycodone in patients with cancer. I. Comparisons of oral with intramuscular codeine and of oral with intramuscular oxycodone.

  1978cited by this paper
• Analgesic studies of codeine and oxycodone in patients with cancer. II. Comparisons of intramuscular oxycodone with intramuscular morphine and codeine.

  1978cited by this paper
• Relief of pain by oral medications. A controlled evaluation of analgesic combinations.

  1974cited by this paper

• Adult Cancer Pain, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology.

  2025cites this paper
• Cancer Pain Is Not One-Size-Fits-All: Evolving from Tradition to Precision

  2025cites this paper
• Weniger ist nicht mehr, aber genauso gut. Der Verzicht auf eine axilläre Lymphknotendissektion ist bei adäquater adjuvanter Therapie möglich

  2024cites this paper
• The Effects of Massage Therapy in Decreasing Pain and Anxiety in Post-Surgical Patients With Breast Cancer: A Systematic Review and Meta-Analysis

  2024cites this paper
• Shifting views on cancer pain management: a systematic review and network meta-analysis.

  2024cites this paper
• Oxycodone: A Current Perspective on Its Pharmacology, Abuse, and Pharmacotherapeutic Developments

  2023cites this paper
• Positive predictive value of axillary lymph node cortical thickness and nodal, clinical, and tumor characteristics in newly diagnosed breast cancer patients

  2023cites this paper
• Effects of oxycodone hydrochloride sustained-release tablets and morphine hydrochloride sustained-release tablets on peripheral blood T cell levels in advanced lung squamous cell carcinoma with moderate to severe cancer pain

  2023cites this paper
• Safety and efficacy of etomidate in combination with oxycodone in painless gastroscopic procedures in the elderly: A prospective randomized controlled trial study

  2023cites this paper
• Use of Opioids for Adults With Pain From Cancer or Cancer Treatment: ASCO Guideline

  2022cites this paper
• ENhANCE trial protocol: A multi-centre, randomised, phase IV trial comparing the efficacy of oxycodone/naloxone prolonged release (OXN PR) versus oxycodone prolonged release (Oxy PR) tablets in patients with advanced cancer

  2022cites this paper
• Opioids for pain.

  2022cites this paper
• Clinical Observation of the Effects of Oral Opioid on Inflammatory Cytokines and Gut Microbiota in Patients with Moderate to Severe Cancer Pain: A Retrospective Cohort Study

  2022cites this paper
• Direct intraoperative versus percutaneous computed tomographyguided celiac plexus neurolysis in non-resectable pancreatic cancer: A randomized, controlled, non-inferiority study.

  2022cites this paper
• Oxycodone relieves permeability damage and apoptosis of oxygen-glucose deprivation/reoxygenation-induced brain microvascular endothelial cells through ras homolog family member A (RhoA)/ Rho-associated coiled-coil containing kinases (ROCK)/ myosin light chain 2 (MLC2) signal

  2022cites this paper
• Direct intraoperative versus percutaneous computed tomographyguided celiac plexus neurolysis in non-resectable pancreatic cancer: A randomized, controlled, non-inferiority study.

  2021cites this paper
• Opioids in cancer: The κ-opioid receptor

  2021cites this paper
• Activation of Opioid Receptors Attenuates Ischemia/Reperfusion Injury in Skeletal Muscle Induced by Tourniquet Placement

  2021cites this paper
• Multifarious Targets and Recent Developments in the Therapeutics for the Management of Bone Cancer Pain.

  2021cites this paper
• Prescribing Prevalence of Medications With Potential Genotype-Guided Dosing in Pediatric Patients

  2020cites this paper
• Management of Cancer Pain in Primary, Secondary, and Palliative Care

  2020cites this paper
• Oxycodone self-administration activates the mitogen-activated protein kinase/ mitogen- and stress-activated protein kinase (MAPK-MSK) signaling pathway in the rat dorsal striatum

  2020cites this paper
• Post‐operative opioid‐related adverse events with intravenous oxycodone compared to morphine: A randomized controlled trial

  2020cites this paper
• Escalated Oxycodone Self-Administration and Punishment: Differential Expression of Opioid Receptors and Immediate Early Genes in the Rat Dorsal Striatum and Prefrontal Cortex

  2020cites this paper
• Oxycodone versus morphine for cancer pain titration: A systematic review and pharmacoeconomic evaluation

  2020cites this paper
• Therapie des Tumorschmerzes mit Opioiden

  2020cites this paper
• Endoscopic Ultrasound-Guided Celiac Plexus Interventions

  2020cites this paper
• Anti-nociceptive and anti-inflammatory effects of the ethanol extract of Arenga pinnata (Wurmb) Merr. fruit.

  2019cites this paper
• EUS-guided celiac ganglion radiofrequency ablation versus celiac plexus neurolysis for palliation of pain in pancreatic cancer: a randomized controlled trial (with videos).

  2019cites this paper
• Efficacy of controlled-release oxycodone for reducing pain due to oral mucositis in nasopharyngeal carcinoma patients treated with concurrent chemoradiotherapy: a prospective clinical trial

  2019cites this paper
• Pain management in patients with malignant mesothelioma: challenges and solutions

  2019cites this paper
• Testing for midazolam and oxycodone in blood after formalin-embalmment: about a complex medico-legal case.

  2019cites this paper
• Escalated oxycodone self-administration causes differential striatal mRNA expression of FGFs and IEGs following abstinence-associated incubation of oxycodone craving.

  2019cites this paper
• Adult Cancer Pain, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology.

  2019cites this paper
• How to interpret the results of comparative drug tests? Statistical analysis methods: standardized SMD mean difference and mean difference calculated by the LSMD least squares method

  2019cites this paper
• Effects of Adding Oxycodone to Ropivacaine on Labor Analgesia

  2019cites this paper
• Protective Effects of Dexmedetomidine and Oxycodone in Patients Undergoing Limb Ischemia-Reperfusion

  2019cites this paper
• Clinical Approaches to Adult Cancer Pain

  2019cites this paper
• Sustainable access to appropriate opioids for palliative care patients in Australia-preventing the need for crisis management

  2019cites this paper
• Efficacy And Safety Of Controlled-Release Oxycodone For The Management Of Moderate-To-Severe Chronic Non-Cancer Pain In Japanese Patients: Results From An Open-Label Study

  2019cites this paper
• PharmGKB summary: oxycodone pathway, pharmacokinetics

  2018cites this paper
• Oxycodone ameliorates the inflammatory response induced by lipopolysaccharide in primary microglia

  2018cites this paper
• Efficacy and safety of titration with controlled-release oxycodone versus immediate-release morphine in patients with moderate cancer pain

  2018cites this paper
• Challenges and concerns of persistent opioid use in cancer patients

  2018cites this paper
• Updates in palliative care – overview and recent advancements in the pharmacological management of cancer pain

  2018cites this paper
• Efficacy, tolerability and acceptability of oxycodone for cancer-related pain in adults: an updated Cochrane systematic review

  2018cites this paper
• Treatment of Pain in Cancer: Towards Personalised Medicine

  2018cites this paper
• Intractable Central Pain in a Patient With Diffuse Glioma

  2018cites this paper
• Oral nonsteroidal anti-inflammatory drugs (NSAIDs) for cancer pain in adults.

  2017cites this paper
• Opioids for cancer pain - an overview of Cochrane reviews.

  2017cites this paper
• Tramadol with or without paracetamol (acetaminophen) for cancer pain.

  2017cites this paper
• Addressing the barriers related with opioid therapy for management of chronic pain in India.

  2017cites this paper
• Oral paracetamol (acetaminophen) for cancer pain.

  2017cites this paper
• Gender difference in prescription opioid abuse: A focus on oxycodone and hydrocodone.

  2016cites this paper
• Oxycodone for pain in fibromyalgia in adults.

  2016cites this paper
• Outcomes of Treatment with Opioids - the role of clinical, pharmacokinetic and genetic factors

  2016cites this paper
• Oxycodone for neuropathic pain in adults.

  2016cites this paper
• Oral morphine for cancer pain.

  2016cites this paper
• Methadone is superior to fentanyl in treating neuropathic pain in patients with head-and-neck cancer.

  2016cites this paper
• Comparison of the Tolerability Profile of Controlled-Release Oral Morphine and Oxycodone for Cancer Pain Treatment. An Open-Label Randomized Controlled Trial.

  2016influential citation
• Revue systématique et méta-analyse en médecine palliative

  2015cites this paper
• Oxycodone for Cancer Pain in Adult Patients.

  2015cites this paper
• Buprenorphine for treating cancer pain.

  2015cites this paper
• A Systematic Review of Prospective Studies Reporting Adverse Events of Commonly Used Opioids for Cancer-Related Pain: A Call for the Use of Standardized Outcome Measures.

  2015cites this paper